Frank Smithuis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4648050/publications.pdf

Version: 2024-02-01

279701 206029 2,474 62 23 48 citations h-index g-index papers 69 69 69 2839 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal, 2022, 21, 106.	0.8	1
2	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	2.0	33
3	Inter-prescriber variability in the decision to prescribe antibiotics to febrile patients attending primary care in Myanmar. JAC-Antimicrobial Resistance, 2021, 3, dlaa118.	0.9	2
4	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 2021, 6, 64.	0.9	11
5	Ambulatory induction phase treatment of cryptococcal meningitis in HIV integrated primary care clinics, Yangon, Myanmar. BMC Infectious Diseases, 2021, 21, 375.	1.3	2
6	Geographical distribution of Burkholderia pseudomallei in soil in Myanmar. PLoS Neglected Tropical Diseases, 2021, 15, e0009372.	1.3	7
7	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1579-1589.	4.6	8
8	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. ELife, 2021, 10, .	2.8	53
9	The 20-minute whole blood clotting test (20WBCT) for snakebite coagulopathy—A systematic review and meta-analysis of diagnostic test accuracy. PLoS Neglected Tropical Diseases, 2021, 15, e0009657.	1.3	22
10	Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. Malaria Journal, 2021, 20, 366.	0.8	3
11	Enhanced melioidosis surveillance in patients attending four tertiary hospitals in Yangon, Myanmar. Epidemiology and Infection, 2021, 149, 1-23.	1.0	2
12	Myanmar Burkholderia pseudomallei strains are genetically diverse and originate from Asia with phylogenetic evidence of reintroductions from neighbouring countries. Scientific Reports, 2020, 10, 16260.	1.6	11
13	Integration of HIV services with primary care in Yangon, Myanmar: a retrospective cohort analysis. HIV Medicine, 2020, 21, 547-556.	1.0	4
14	Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial. Trials, 2020, 21, 974.	0.7	13
15	Genetic analysis of the orthologous crt and $mdr1$ genes in Plasmodium malariae from Thailand and Myanmar. Malaria Journal, 2020, 19, 315.	0.8	1
16	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	6.3	182
17	Evaluation of the forum theatre approach for public engagement around antibiotic use in Myanmar. PLoS ONE, 2020, 15, e0235625.	1.1	14
18	Polymorphic markers for identification of parasite population in Plasmodium malariae. Malaria Journal, 2020, 19, 48.	0.8	3

#	Article	IF	CITATIONS
19	Causes of fever in primary care in Southeast Asia and the performance of C-reactive protein in discriminating bacterial from viral pathogens. International Journal of Infectious Diseases, 2020, 96, 334-342.	1.5	8
20	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	3.9	32
21	A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. PLoS Neglected Tropical Diseases, 2020, 14, e0008109.	1.3	4
22	Title is missing!. , 2020, 17, e1003393.		0
23	Title is missing!. , 2020, 17, e1003393.		0
24	Title is missing!. , 2020, 17, e1003393.		0
25	Title is missing!. , 2020, 17, e1003393.		0
26	Title is missing!. , 2020, 17, e1003393.		0
27	Title is missing!. , 2020, 14, e0008109.		0
28	Title is missing!. , 2020, 14, e0008109.		0
29	Title is missing!. , 2020, 14, e0008109.		0
30	Title is missing!. , 2020, 14, e0008109.		0
31	Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity. Journal of Infectious Diseases, 2019, 220, 100-104.	1.9	19
32	The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. PLoS Medicine, 2019, 16, e1002745.	3.9	105
33	Economic considerations support C-reactive protein testing alongside malaria rapid diagnostic tests to guide antimicrobial therapy for patients with febrile illness in settings with low malaria endemicity. Malaria Journal, 2019, 18, 442.	0.8	4
34	Effect of point-of-care C-reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: an open-label, randomised, controlled trial. The Lancet Global Health, 2019, 7, e119-e131.	2.9	61
35	Malaria elimination in remote communities requires integration of malaria control activities into general health care: an observational study and interrupted time series analysis in Myanmar. BMC Medicine, 2018, 16, 183.	2.3	40
36	Effectiveness and safety of 3 and 5Âday courses of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malaria Journal, 2018, 17, 258.	0.8	27

#	Article	lF	Citations
37	Genetic polymorphisms in the circumsporozoite protein of Plasmodium malariae show a geographical bias. Malaria Journal, 2018, 17, 269.	0.8	12
38	Melioidosis in Myanmar. Tropical Medicine and Infectious Disease, 2018, 3, 28.	0.9	12
39	Genetic diversity of three surface protein genes in Plasmodium malariae from three Asian countries. Malaria Journal, 2018, 17, 24.	0.8	9
40	Measuring Mosquito-borne Viral Suitability in Myanmar and Implications for Local Zika Virus Transmission. PLOS Currents, 2018, 10, .	1.4	10
41	Community engagement and the social context of targeted malaria treatment: a qualitative study in Kayin (Karen) State, Myanmar. Malaria Journal, 2017, 16, 75.	0.8	53
42	A current perspective on antimicrobial resistance in Southeast Asia. Journal of Antimicrobial Chemotherapy, 2017, 72, 2963-2972.	1.3	139
43	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	1.2	13
44	Malaria community health workers in Myanmar: a cost analysis. Malaria Journal, 2016, 15, 41.	0.8	14
45	Cost effectiveness and resource allocation of Plasmodium falciparum malaria control in Myanmar: a modelling analysis of bed nets and community health workers. Malaria Journal, 2015, 14, 376.	0.8	15
46	Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infectious Diseases, The, 2015, 15, 415-421.	4.6	363
47	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	2.3	37
48	Artemisinin resistance in Myanmar – Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 1002-1003.	4.6	0
49	Treatment Outcomes From the Largest Antiretroviral Treatment Program in Myanmar (Burma). Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e53-e62.	0.9	29
50	CMV retinitis screening and treatment in a resourceâ€poor setting: threeâ€year experience from a primary care HIV/AIDS programme in Myanmar. Journal of the International AIDS Society, 2011, 14, 41-41.	1.2	28
51	In Vivo Parasitological Measures of Artemisinin Susceptibility. Journal of Infectious Diseases, 2010, 201, 570-579.	1.9	133
52	Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infectious Diseases, The, 2010, 10, 673-681.	4.6	168
53	Safety and Efficacy of Dihydroartemisinin-Piperaquine in Falciparum Malaria: A Prospective Multi-Centre Individual Patient Data Analysis. PLoS ONE, 2009, 4, e6358.	1.1	91
54	The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malaria Journal, 2008, 7, 149.	0.8	42

#	Article	IF	CITATIONS
55	Cytomegalovirus Retinitis: The Neglected Disease of the AIDS Pandemic. PLoS Medicine, 2007, 4, e334.	3.9	105
56	Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet, The, 2006, 367, 2075-2085.	6.3	133
57	In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up. Antimicrobial Agents and Chemotherapy, 2004, 48, 4271-4280.	1.4	95
58	Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar. Tropical Medicine and International Health, 2004, 9, 1184-1190.	1.0	22
59	Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 182-192.	0.7	24
60	Fake artesunate in southeast Asia. Lancet, The, 2001, 357, 1948-1950.	6.3	202
61	Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 468-472.	0.7	36
62	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 0, 6, 64.	0.9	11